Form 4: Neurogene Inc. President and CFO Acquires 24,000 Shares

Neurogene Inc.'s President and CFO, Christine Mikail Cvijic, purchased 24,000 shares of common stock at a weighted average price of $20.475.

Summary

• Christine Mikail Cvijic, President and CFO of Neurogene Inc., acquired 24,000 shares of the company's common stock on November 22, 2024.
• The shares were purchased at a weighted average price of $20.475 per share.
• The transactions occurred at prices ranging from $20.33 to $20.92.
• Following the transaction, Ms. Cvijic beneficially owns a total of 76,844 shares, including 24,000 shares held jointly with her spouse.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as it shows a key executive investing in the company's stock, which is generally seen as a sign of confidence. However, it is a routine filing and not a major event.

Positives

• The purchase of shares by a key executive like the President and CFO can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The reporting requirements are consistent across all companies and are designed to ensure transparency in insider trading.
• Similar filings are made by executives at companies like Biogen (BIIB) and Vertex Pharmaceuticals (VRTX) when they trade their company's stock.

Stakeholder Impact

• The purchase of shares by the CFO may positively influence investor confidence.

Key Dates

Keywords

Neurogene Inc., insider trading, stock purchase, Christine Mikail Cvijic, executive, common stock, NGNE